Back to top
more

Vertex Pharmaceuticals Incorporated (VRTX)

(Delayed Data from NSDQ)

$194.80 USD

194.80
3,336,712

+1.78 (0.92%)

Updated Jun 14, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (212 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for VRTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Vertex Pharmaceuticals Incorporated falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 6,659 3,808 3,168 2,090 1,482
Receivables 885 634 410 281 201
Notes Receivable 0 0 0 0 0
Inventories 281 168 124 112 78
Other Current Assets 308 214 141 166 71
Total Current Assets 8,133 4,823 3,843 2,649 1,832
Net Property & Equipment 959 745 812 789 698
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 883 1,191 1,500 0 0
Intangibles 1,402 1,402 50 79 335
Deposits & Other Assets 49 158 41 28 32
Total Assets 11,752 8,318 6,246 3,546 2,897
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 155 88 111 74 61
Current Portion Long-Term Debt 0 0 0 0 300
Current Portion Capital Leases 0 0 10 23 19
Accrued Expenses 1,405 1,117 605 446 321
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 317 130 395 265 90
Total Current Liabilities 1,878 1,335 1,120 807 793
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 8 141
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 539 539 582 584 521
Other Non-Current Liabilities 298 360 109 104 104
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 3,065 2,233 1,811 1,504 1,559
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 3 3 3 2
Capital Surplus 7,894 7,938 7,421 7,157 6,507
Retained Earnings 859 -1,853 -2,989 -5,120 -5,374
Other Equity -68 -2 1 2 203
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 8,687 6,085 4,435 2,042 1,338
Total Liabilities & Shareholder's Equity 11,752 8,318 6,246 3,546 2,897
Total Common Equity 8,687 6,085 4,435 2,042 1,338
Shares Outstanding 260.00 257.10 255.50 252.90 248.30
Book Value Per Share 33.41 23.67 17.36 8.08 5.39

Fiscal Year End for Vertex Pharmaceuticals Incorporated falls in the month of December.

All items in Millions except Per Share data.

3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Assets          
Cash & Equivalents 6,924 6,659 6,151 5,451 4,190
Receivables 978 885 792 792 845
Notes Receivable 0 0 0 0 0
Inventories 299 281 245 219 187
Other Current Assets 339 308 270 233 224
Total Current Assets 8,539 8,133 7,458 6,694 5,446
Net Property & Equipment 986 959 921 728 736
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 816 883 1,148 1,215 1,148
Intangibles 1,402 1,402 1,402 1,402 1,402
Deposits & Other Assets 49 49 372 177 161
Total Assets 12,115 11,752 11,302 10,216 8,893
Liabilities & Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 128 155 108 101 101
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 1,532 1,405 1,704 1,545 1,258
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 284 317 193 152 180
Total Current Liabilities 1,944 1,878 2,004 1,799 1,539
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 530 539 547 522 533
Other Non-Current Liabilities 292 618 376 360
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 3,135 3,065 3,168 2,697 2,432
Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 3 3 3 3
Capital Surplus 7,499 7,894 7,917 7,944 7,696
Retained Earnings 1,512 859 254 -413 -1,250
Other Equity -33 -68 -41 -14 13
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 8,980 8,687 8,133 7,519 6,462
Total Liabilities & Shareholder's Equity 12,115 11,752 11,302 10,216 8,893
Total Common Equity 8,980 8,687 8,133 7,519 6,462
Shares Outstanding 258.80 260.00 260.00 260.40 259.20
Book Value Per Share 34.70 33.41 31.28 28.88 24.93